July 6, 2011 -- MingSight Pharma of San Diego announced a new JV with Shenzhen Relin Medicine that will develop a treatment for diabetic retinopathy for use in China. The JV will own China rights to an innovative molecule, MS-553, that MingSight in-licensed from Pfizer last October. MS-553 is a first-in-class oral compound. More details....
Stock Symbol: (NYSE: PFE)
